Health & Biotech
Check out the latest Health news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
PharmAust files groundbreaking MND/ALS clinical data with the FDA
Health & Biotech
International cardiometabolic expert to join Race Oncology’s scientific advisory board
Health & Biotech
EZZ products to gain exposure to increasing Chinese tourist numbers at Auckland airport under duty-free deal
Health & Biotech
Neurotech extends clinical trials for the $US2bn Rett Syndrome market
Health & Biotech
Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial
Health & Biotech
‘A key milestone’: Dimerix ACTION3 Phase 3 trial interim results meet endpoint
Health & Biotech
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
Health & Biotech
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical studies and partnering
Health & Biotech
Nova Eye Medical hits new US sales record following improved uptake of iTrack Advance products
Tech
SafeWatch to call time on workplace mental health crisis
Health & Biotech
PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy
Health & Biotech
Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024
Stockhead TV
What’s in store for 2024: Paradigm Biopharmaceuticals
Health & Biotech
Regal cornerstones $14m CardieX raise as medtech prepares to debut world-first vascular biometric monitor
Health & Biotech
PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS
Health & Biotech
Neurotech reports sustained clinical progress in PANDAS/PANS patients during Phase I/II extension study
Health & Biotech
LTR Pharma firms up study for erectile dysfunction with patient recruitment
Health & Biotech
FDA shows the way for accelerated approval of PharmAust’s monepantel in MND
Stockhead TV
Long Shortz with AROA Biosurgery: A chance at a smoother recovery from a Mastectomy? Thanks Enivo
Health & Biotech
PharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’
Health & Biotech
Countdown on to AdAlta trial results as biotech advances partner discussions
Health & Biotech
EZZ expands range with launch of three new health and wellness products
Health & Biotech
‘Monumental’– Bioxyne subsidiary awarded Australia’s first GMP licence to manufacture psilocybin and MDMA
Health & Biotech
ASX Health Stocks: Radiopharm’s results published; ProMedicus launches on Apple Vision Pro
Stockhead TV
What’s in Store for 2024: Race Oncology
News
Morgan Stanley name drops ASX-listed Ebos as likely to fatten-up on Asia’s Ozempic weight-loss craze
Experts
MoneyTalks: Why this portfolio manager is bullish on the most shorted lithium stock on the ASX
Health & Biotech
PharmAust gets ethics committee green light for open-label MND extension study
Health & Biotech
Neurotech gets green light to start phase I/II cerebral palsy trial
Health & Biotech
Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth
Health & Biotech
FDA offers PharmAust clear guidance for orphan drug designation approval
Health & Biotech
Enivo pilot clinical study shows promise for reducing mastectomy complications
Health & Biotech
Neurotech moves to show economic advantage of autism treatment as Phase II/III trial results due soon
Health & Biotech
Healthy balance sheet with no debt, this overlooked ASX health stock has been paying dividends for years
Health & Biotech
AdAlta advancing partnering programs as AD-214 participants receive final dose
Coinhead
The launch of bullion-backed ETFs shot gold into the stratosphere. Could SEC approval do the same for Bitcoin?
Stockhead TV
What’s in store for 2024: EZZ Life Science
Health & Biotech
PharmAust partners with US-based Berry Consultants for Phase 2/3 study
Stockhead TV
What’s in store for 2024: Neurotech International
Stockhead TV
What’s in store for 2024: Aroa Biosurgery
Health & Biotech
ScoPo’s Powerplays: ASX healthcare 0.3% up as focus shifts to M&A activity in 2024
Health & Biotech
ASX Health Stocks: US bound Telix plans dual listing on the NASDAQ
Stockhead TV
What’s in store for 2024: AdAlta
Health & Biotech
PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24
Health & Biotech
Part 1: ASX biotechs with catalysts looking to pop in 2024
Health & Biotech
Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust
Health & Biotech
Santa (and ATO) delivers PharmAust $550k cash boost for Christmas
Load More